CD70 blocking reverted regulatory T cell-mediated suppression and thus reinvigorated CD8+ T-cell immunity. Anti-CD70+ anti-PD-1 therapy was evaluated in xenograft-derived organoids and humanized mice, exhibiting an improved tumor-killing efficacy.
[Nature Communications]